ALSO NOTED: Government could force doc disclosures; Barr sues Watson over Seasonique patent;

> The government is considering requiring pharma companies to disclose their doc-consulting deals as part of any settlement agreements. Report | Report

> Duramed, a Barr Pharmaceuticals subsidiary, filed a patent infringement suit against Watson Pharmaceuticals, alleging it had infringed on its patent for the contraceptive Seasonique. Release

> Teva sued the FDA for denying its exclusivity period for its version of the antipsychotic Risperdal, which goes off patent this year. Release

> Genzyme launched its phosphate-binding drug Renvela for use in dialysis patients in the U.S. Release

> Baxter may test its immune booster Gammagard against Alzheimer's after a medical claims analysis indicated the risk of developing the disease could be reduced in patients previously treated with the med. Report

> A new study showed that Novartis' cancer drug Gleevec could harm fetal development if the child was conceived during treatment. Report

> With no "firm" buyout offers coming in, PDL BioPharma has decided to axe 260 workers--on top of the 320 layoffs already announced--and take itself off the market. Report

> After concluding that its late-stage trial of MC-1 failed to hit its primary endpoint, Medicure has announced plans to slash 50 workers and full-time consultants. Report

> The FDA is sending signals that it will start to let deadlines for drug approvals go by the wayside. Report

And Finally... Surgery may effectively cure Type II diabetes, according to a new study in Diabetes Care. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.